Caplin Point Laboratories Limited Share Price

Equities

CAPLIPOINT

INE475E01026

Pharmaceuticals

Market Closed - Bombay S.E. 03:30:50 13/06/2024 pm IST 5-day change 1st Jan Change
1,398 INR -4.44% Intraday chart for Caplin Point Laboratories Limited +7.29% +3.12%
Sales 2024 16.94B 203M Sales 2025 * 19.67B 235M Capitalization 111B 1.33B
Net income 2024 4.57B 54.72M Net income 2025 * 5.23B 62.57M EV / Sales 2024 5.91 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 5.65 x
P/E ratio 2024
22 x
P/E ratio 2025 *
21.2 x
Employees 1,642
Yield 2024 *
0.22%
Yield 2025 *
0.23%
Free-Float 25.34%
More Fundamentals * Assessed data
Dynamic Chart
Caplin Point Laboratories Limited Appoints Thiagaraja Manikandan as Chief Transformation & Digital Officer CI
Caplin Point Arm Gets US FDA's Nod for Phenylephrine Hydrochloride Ophthalmic Solution MT
Caplin Point Laboratories to Seek Acquisitions CI
Transcript : Caplin Point Laboratories Limited, Q4 2024 Earnings Call, May 16, 2024
Caplin Point Laboratories Limited Declares an Interim Dividend for the Financial Year Ended March 31, 2024 CI
Caplin Point Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Caplin Point Laboratories Gets Colombian Drug Regulator's Approval for Soft Gel Capsules Unit in India MT
Caplin Point Laboratories Limited Receives Colombia's INVIMA Approval for Its Softgel Capsules Division At Puducherry CI
Caplin Point Arm Gets US FDA Final Nod for Ofloxacin Ophthalmic Solution MT
Caplin Point Unit Receives US FDA Nod for Eye Treatment Medication MT
Caplin Steriles Limited, A Subsidiary of Caplin Point Laboratories Limited Gets USFDA Approval for Ketorolac Tromethamine Ophthalmic Solution CI
Caplin Point Laboratories Arm Starts Operations of Oncology Facility at Kakkalur, India MT
Caplin One Labs Limited, a Wholly Owned Subsidiary of Caplin Point Laboratories Limited Successfully Completes New Oncology (Anti-Cancer) Facility, Commences Operations CI
Transcript : Caplin Point Laboratories Limited, Q3 2024 Earnings Call, Feb 09, 2024
Caplin Point Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
More news
1 day-4.44%
1 week+7.29%
Current month+8.44%
1 month+7.10%
3 months+9.68%
6 months+14.66%
Current year+3.12%
More quotes
1 week
1 280.10
Extreme 1280.1
1 543.00
1 month
1 221.00
Extreme 1221
1 543.00
Current year
1 221.00
Extreme 1221
1 617.80
1 year
781.25
Extreme 781.25
1 617.80
3 years
575.00
Extreme 575
1 617.80
5 years
180.00
Extreme 180
1 617.80
10 years
32.24
Extreme 32.24
1 617.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 69 28/15/28
Director of Finance/CFO - 19/16/19
Chief Administrative Officer - -
Members of the board TitleAgeSince
Chairman 71 -
Chief Operating Officer - 01/10/01
Chief Executive Officer 69 28/15/28
More insiders
Date Price Change Volume
13/24/13 1,398 -4.44% 23 409
12/24/12 1,463 +0.40% 4,283
11/24/11 1,458 -1.22% 7,604
10/24/10 1,476 +8.03% 94,040
07/24/07 1,366 +4.79% 5,912

Delayed Quote Bombay S.E., June 13, 2024 at 03:30 pm IST

More quotes
Caplin Point Laboratories Limited is an India-based pharmaceutical company. The Company is engaged in producing, developing, and marketing a range of generic formulations and branded products and exporting to overseas markets. Its products include tablets, dry syrups (bottles), soft gels, capsules, suppositories, liquid syrups (bottles), liquid injectables in ampoules and vials, lyophilized vials, prefilled syringes (PFS), emulsion injection in ampoules and vials, ophthalmic droppers, pre-mix bags, topicals and sachets (liquids and powders). It also manufactures a range of ointments, creams, gels and lotions. Its principal research and development facilities are in Tamil Nadu, India. Its principal manufacturing facility is in Puducherry, India. It has presence in Latin America (LATAM), Southern Africa and Francophone Africa along with a presence in United States of America and European region. The Company’s subsidiaries include Caplin Point Far East Limited and Caplin Steriles Limited.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1,463 INR
Average target price
1,569 INR
Spread / Average Target
+7.19%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. CAPLIPOINT Stock